Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides
- PMID: 22867060
- DOI: 10.1089/AID.2012.0049
Understanding factors that modulate HIV infection at the female genital tract mucosae for the rationale design of microbicides
Abstract
Women are now becoming the pivot of the epidemiological spread of HIV infection worldwide, especially in developing countries. Therefore, research to develop an efficient microbicide is now a priority for the prevention of HIV-1 acquisition in exposed women. However, recent disappointing failures in microbicide clinical trials revealed major gaps in basic and applied knowledge that hinder the development of effective microbicide formulations. Indeed, the inhibitory power of microbicide molecules may be affected by several physiological and immunological factors present in male and female genital tracts. Furthermore, mucosal crossing of HIV-1 to increase the ability to reach the submucosal target cells (macrophages, lymphocytes, and dendritic cells) may be modulated by supraepithelial factors such as seminal complement components (opsonized HIV-1), by epithelial factors released in the submucosal microenvironment such as antimicrobial soluble factors, cytokines, and chemokines, and by potent intraepithelial and submucosal innate immunity. The design of vaginal microbicide formulations should take into account an understanding of the intimate mechanisms involved in the crossing of HIV through the female genital mucosae, in the context of a mixture of both male and female genital fluids.
Similar articles
-
Increased COX-2 expression in human vaginal epithelial cells exposed to nonoxynol-9, a vaginal contraceptive microbicide that failed to protect women from HIV-1 infection.Am J Reprod Immunol. 2011 Jun;65(6):569-77. doi: 10.1111/j.1600-0897.2010.00964.x. Epub 2011 Jan 18. Am J Reprod Immunol. 2011. PMID: 21241401
-
Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials.Contraception. 2008 Feb;77(2):122-9. doi: 10.1016/j.contraception.2007.10.006. Epub 2007 Dec 27. Contraception. 2008. PMID: 18226677 Clinical Trial.
-
Vaginal gel formulation based on theaflavin derivatives as a microbicide to prevent HIV sexual transmission.AIDS Res Hum Retroviruses. 2012 Nov;28(11):1498-508. doi: 10.1089/AID.2012.0084. Epub 2012 Sep 11. AIDS Res Hum Retroviruses. 2012. PMID: 22867271
-
HIV infection in the female genital tract: discrete influence of the local mucosal microenvironment.Am J Reprod Immunol. 2010 Jun;63(6):566-75. doi: 10.1111/j.1600-0897.2010.00843.x. Epub 2010 Mar 29. Am J Reprod Immunol. 2010. PMID: 20384619 Review.
-
Vaginal microbicides to prevent human immunodeficiency virus infection in women: perspectives on the female genital tract, sexual maturity and mucosal inflammation.Best Pract Res Clin Obstet Gynaecol. 2012 Aug;26(4):441-9. doi: 10.1016/j.bpobgyn.2012.02.002. Epub 2012 Mar 17. Best Pract Res Clin Obstet Gynaecol. 2012. PMID: 22429786 Review.
Cited by
-
Vaginal concentrations of lactic acid potently inactivate HIV.J Antimicrob Chemother. 2013 Sep;68(9):2015-25. doi: 10.1093/jac/dkt156. Epub 2013 May 8. J Antimicrob Chemother. 2013. PMID: 23657804 Free PMC article.
-
Role of Complement Receptors (CRs) on DCs in Anti-HIV-1 Immunity.Front Immunol. 2020 Nov 3;11:572114. doi: 10.3389/fimmu.2020.572114. eCollection 2020. Front Immunol. 2020. PMID: 33224139 Free PMC article. Review.
-
3-Hydroxyphthalic Anhydride- Modified Rabbit Anti-PAP IgG as a Potential Bifunctional HIV-1 Entry Inhibitor.Front Microbiol. 2018 Jun 19;9:1330. doi: 10.3389/fmicb.2018.01330. eCollection 2018. Front Microbiol. 2018. PMID: 29971062 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical